Hypoxia: A Double-Edged Sword in Cancer Therapy.
Hypoxia is a common feature of malignant tumors. There is an interactive connection between hypoxia and chemoresistance, radioresistance, invasiveness, and angiogenesis. Therefore, tumor hypoxia has been considered as a validated target for treating cancer. This review focuses on the role of hypoxia on chemoresistance and radioresistance. In addition, we address several approaches targeting tumor hypoxia, known as hypoxia-targeted therapy.
a Research Center for Molecular Medicine, Hamadan University of Medical Sciences , Hamadan , Iran.
Hamed
H
Manoochehri Khoshinani
a Research Center for Molecular Medicine, Hamadan University of Medical Sciences , Hamadan , Iran.
Saeid
S
Afshar
a Research Center for Molecular Medicine, Hamadan University of Medical Sciences , Hamadan , Iran.
Rezvan
R
Najafi
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D015316:Genetic Therapy; D006801:Humans; D000860:Hypoxia / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D051793:Hypoxia-Inducible Factor 1 / Q000235:genetics / Q000378:metabolism; D007109:Immunity; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000628:therapy*; D011836:Radiation Tolerance; D015398:Signal Transduction / Q000187:drug effects / Q000528:radiation effects; D059016:Tumor Microenvironment / Q000235:genetics / Q000276:immunology
D000970:Antineoplastic Agents; D051793:Hypoxia-Inducible Factor 1
Chemoresistance; HIF-1; Hypoxia; Hypoxia-targeted therapy; Radioresistance